| Molecular formula | C62H98N16O22 |
|---|
| Molecular weight | 1419.5 g/mol |
|---|
| Registered trials | 4 |
|---|
| PubChem CID | 9941957 |
|---|
What BPC-157 is
BPC-157 is a synthetic peptide (molecular formula C62H98N16O22) studied in early-stage clinical research. It has no FDA-approved label, no approved brand name, and no cleared indication for any condition. It is listed in PubChem under CID 9941957. Any use outside of registered research settings is not supported by an approved drug label.
Trial footprint
Four trials involving BPC-157 are currently registered. Among the sample of studies available, one Phase 1 trial is examining recovery after rotator cuff repair surgery and has not yet begun recruiting. A separate Phase 1 safety and pharmacokinetics trial (PCO-02) has an unknown status. A Phase 2 trial looking at acute hamstring muscle strain repair is currently recruiting participants. These studies reflect the early and limited nature of clinical investigation into this compound.
FAQ
No. BPC-157 has no FDA-approved label, no approved indication, and no approved brand name. It remains an unapproved research compound.
BPC-157 is a synthetic peptide with the molecular formula C62H98N16O22. It is catalogued in PubChem under CID 9941957.
There are currently four registered clinical trials involving BPC-157. These include Phase 1 and Phase 2 studies at various stages of recruitment.
Registered trials are examining areas such as recovery after rotator cuff repair surgery and acute hamstring muscle strain repair. None of these trials have established an approved use for the compound.
No adverse event report data is currently available for this compound in the dataset reviewed.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 9941957 ClinicalTrials.gov trial registry
Updated 2026-09-19